Jump to content

Stephen Friend

From Wikipedia, the free encyclopedia
(Redirected from Stephen H. Friend)
Stephen Friend at NightScience 2013 in Paris

Stephen H. Friend is co-founder and director of Sage Bionetworks.[1][2][3]

Formerly Senior Vice-president at Merck & Co. Friend co-founded Rosetta Inpharmatics with Leland H. Hartwell and Leroy Hood in 1996.[4] Much of his research has focused on cancer.[5]

Friend has also held faculty positions at Harvard Medical School and Massachusetts General Hospital. He received his Bachelor of Arts in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University in 1981.[2][6]

In 2008, Friend co-founded and led the nonprofit Sage Bionetworks to change how researchers work together. The aim of the nonprofit was to change the way drug discovery is done to improve patient wait times.[7]

Friend worked at Apple from 2016 to 2017 on their health team, under COO Jeff Williams.[8][9]

Recognition

[edit]

Friend was named an Ashoka Fellow by Ashoka: Innovators for the Public in 2011.[10]

Selected bibliography

[edit]
  • Bartz, S. R.; Zhang, Z; Burchard, J; Imakura, M; Martin, M; Palmieri, A; Needham, R; Guo, J; Gordon, M; Chung, N; Warrener, P; Jackson, A. L.; Carleton, M; Oatley, M; Locco, L; Santini, F; Smith, T; Kunapuli, P; Ferrer, M; Strulovici, B; Friend, S. H.; Linsley, P. S. (2006). "Small interfering RNA screens reveal enhanced cisplatin cytotoxicity in tumor cells having both BRCA network and TP53 disruptions". Molecular and Cellular Biology. 26 (24): 9377–86. doi:10.1128/MCB.01229-06. PMC 1698535. PMID 17000754.
  • Radich, J. P.; Dai, H; Mao, M; Oehler, V; Schelter, J; Druker, B; Sawyers, C; Shah, N; Stock, W; Willman, C. L.; Friend, S; Linsley, P. S. (2006). "Gene expression changes associated with progression and response in chronic myeloid leukemia". Proceedings of the National Academy of Sciences. 103 (8): 2794–9. Bibcode:2006PNAS..103.2794R. doi:10.1073/pnas.0510423103. PMC 1413797. PMID 16477019.
  • Dai, H; Van't Veer, L; Lamb, J; He, Y. D.; Mao, M; Fine, B. M.; Bernards, R; Van De Vijver, M; Deutsch, P; Sachs, A; Stoughton, R; Friend, S (2005). "A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients". Cancer Research. 65 (10): 4059–66. doi:10.1158/0008-5472.CAN-04-3953. PMID 15899795.
  • Lampe, J. W.; Stepaniants, S. B.; Mao, M; Radich, J. P.; Dai, H; Linsley, P. S.; Friend, S. H.; Potter, J. D. (2004). "Signatures of environmental exposures using peripheral leukocyte gene expression: Tobacco smoke". Cancer Epidemiology, Biomarkers & Prevention. 13 (3): 445–53. doi:10.1158/1055-9965.445.13.3. PMID 15006922. S2CID 7624677.
  • Van 't Veer, L. J.; Dai, H; Van De Vijver, M. J.; He, Y. D.; Hart, A. A.; Bernards, R; Friend, S. H. (2003). "Expression profiling predicts outcome in breast cancer". Breast Cancer Research. 5 (1): 57–8. doi:10.1186/bcr562. PMC 154139. PMID 12559048.
  • Van De Vijver, M. J.; He, Y. D.; Van't Veer, L. J.; Dai, H; Hart, A. A.; Voskuil, D. W.; Schreiber, G. J.; Peterse, J. L.; Roberts, C; Marton, M. J.; Parrish, M; Atsma, D; Witteveen, A; Glas, A; Delahaye, L; Van Der Velde, T; Bartelink, H; Rodenhuis, S; Rutgers, E. T.; Friend, S. H.; Bernards, R (2002). "A gene-expression signature as a predictor of survival in breast cancer". New England Journal of Medicine. 347 (25): 1999–2009. doi:10.1056/NEJMoa021967. hdl:1874/15577. PMID 12490681.
  • Lamb, J. R.; Zhang, C; Xie, T; Wang, K; Zhang, B; Hao, K; Chudin, E; Fraser, H. B.; Millstein, J; Ferguson, M; Suver, C; Ivanovska, I; Scott, M; Philippar, U; Bansal, D; Zhang, Z; Burchard, J; Smith, R; Greenawalt, D; Cleary, M; Derry, J; Loboda, A; Watters, J; Poon, R. T.; Fan, S. T.; Yeung, C; Lee, N. P.; Guinney, J; Molony, C; et al. (2011). "Predictive genes in adjacent normal tissue are preferentially altered by sCNV during tumorigenesis in liver cancer and may rate limiting". PLOS ONE. 6 (7): e20090. Bibcode:2011PLoSO...620090L. doi:10.1371/journal.pone.0020090. PMC 3130029. PMID 21750698.
  • Mihich, E; Feunteun, J; Friend, S (2002). "Thirteenth annual pezcoller symposium: Focusing analytical tools on complexity in cancer". Cancer Research. 62 (13): 3883–7. PMID 12097304.

References

[edit]
  1. ^ Kaiser, J. (2012). "The Visionary". Science. 335 (6069): 651–3. doi:10.1126/science.335.6069.651. PMID 22323794.
  2. ^ a b "Sage Bionetworks Seattle | Directors". Archived from the original on 2012-01-27. Retrieved 2012-02-11.
  3. ^ "Stephen Friend". Nature Reviews Drug Discovery. 7 (2): 114. 2008. doi:10.1038/nrd2509.
  4. ^ Nelson, Bryn; Schadt, E (2009). "Something wiki this way comes". Nature. 458 (7234): 13. doi:10.1038/458013a. PMID 19262635.
  5. ^ Kaiser, J. (2012). "The Visionary". Science. 335 (6069): 651–3. doi:10.1126/science.335.6069.651. PMID 22323794.
  6. ^ "Dr. Stephen Friend, Pediatrics". WebMD. Retrieved 2025-02-28.
  7. ^ "Seattle's Sage Bionetworks seeks a drug-discovery revolution". The Seattle Times. 2012-02-11. Retrieved 2025-02-28.
  8. ^ Farr, Christina (2018-02-06). "Stephen Friend, a well-known health researcher, is out at Apple after less than two years". CNBC. Retrieved 2025-02-28.
  9. ^ Farr, Christina (2019-08-20). "Apple health team faces departures as tensions rise over differing visions for the future". CNBC. Retrieved 2025-02-28.
  10. ^ http://sagebase.org/info/NewsInfoDownloads/SageAshokaRelease6APR2011.pdf[dead link‍]
[edit]
Retrieved from "https://wiki.riteme.site/w/index.php?title=Stephen_Friend&oldid=1278757512"